Meningitis | eHealth News | Page 4

A case of cryptococcal meningitis with false-negative cerebrospinal fluid culture results following receipt of capecitabine has been described in a case report published in the December issue of the Journal of Clinical Pharmacy and Therapeutics.

Antineoplastic Agent Obscures Diagnosis of Fungal Meningitis

HealthDay.com - Dec 17, 2015 0

Cerebrospinal fluid culture results were negative following receipt of capecitabine

Drug-induced aseptic meningitis following trimethoprim use has been described in a research letter published online Nov. 20 in the International Journal of Rheumatic Diseases.

Trimethoprim-Induced Aseptic Meningitis Described

HealthDay.com - Nov 30, 2015 0

Case report describes 87-year-old with 3 episodes; decreasing interval between dose, symptoms

Serogroup B meningococcal vaccination is recommended for adolescents and young adults aged 16 to 23 years to provide short-term protection from most strains of serogroup B meningococcal disease

MenB Vaccine Recommended for 16- to 23-Year-Olds

HealthDay.com - Oct 26, 2015 0

Preferred age for serogroup B meningococcal vaccination is 16 to 18 years

For 11- to 15-year olds

Concomitant Administration of 9vHPV With MCV4/Tdap Feasible

HealthDay.com - Aug 3, 2015 0

Noninferior to intermittent administration of vaccines for 11- to 15-year olds

The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has voted to issue a category B recommendation for use of two serogroup B meningococcal vaccines in patients aged 16 to 23 years for short-term disease prevention

ACIP Recommends MenB Vaccine for 16- to 23-Year-Olds

HealthDay.com - Jul 8, 2015 0

Category B recommendation for short-term protection against meningitis for all aged 16 to 23

An investigational serogroup B meningococcal vaccine seems to have protected vaccinated individuals from the disease during an outbreak

Investigational MenB Vaccine Can Protect Individuals in Outbreak

HealthDay.com - Apr 30, 2015 0

No serogroup B meningococcal disease cases in those who received MenB vaccine in university outbreak

The Bexsero vaccine has been approved by the U.S. Food and Drug Administration to prevent serogroup B meningococcal disease among people aged 10 through 25.

FDA Approves New Meningococcal Disease Vaccine

HealthDay.com - Jan 26, 2015 0

Bexsero is the second vaccine approved in the past three months to prevent this disease

1 2 34Page 4 of 4

Archives